Management von Nebenwirkungen unter Immuncheckpointinhibition

Article Properties
  • Language
    German
  • DOI (url)
    10.1055/a-1723-5962
  • Publication Date
    2023/02/01
  • Journal
    Frauenheilkunde up2date
  • Indian UGC (journal)
  • Refrences
    22
  • Susanne Beyer
  • Alexander König
  • Anna Hester
  • Fabian Trillsch
  • Nadia Harbeck
  • Rachel Würstlein
Cite
Beyer, Susanne, et al. “Management Von Nebenwirkungen Unter Immuncheckpointinhibition”. Frauenheilkunde up2date, vol. 17, no. 01, 2023, pp. 25-44, https://doi.org/10.1055/a-1723-5962.
Beyer, S., König, A., Hester, A., Trillsch, F., Harbeck, N., & Würstlein, R. (2023). Management von Nebenwirkungen unter Immuncheckpointinhibition. Frauenheilkunde up2date, 17(01), 25-44. https://doi.org/10.1055/a-1723-5962
Beyer S, König A, Hester A, Trillsch F, Harbeck N, Würstlein R. Management von Nebenwirkungen unter Immuncheckpointinhibition. Frauenheilkunde up2date. 2023;17(01):25-44.
Refrences
Title Journal Journal Categories Citations Publication Date
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 1,442 2017
Survival with cemiplimab in recurrent cervical cancer New England Journal of Medicine
  • Medicine: Medicine (General)
  • Medicine: Internal medicine
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
 2022
Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients

 Supportive Care in Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General): Medical technology
  • Medicine: Internal medicine: Special situations and conditions: Sports medicine
  • Medicine: Medicine (General)
 10 2022
Nebenwirkungsmanagement von Immuncheckpoint-Inhibitor-Therapien DMW - Deutsche Medizinische Wochenschrift
  • Medicine: Medicine (General)
  • Medicine: Internal medicine
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
 1 2021
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) 2021
Refrences Analysis
Category Category Repetition
Medicine: Medicine (General)11
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens5
Medicine: Internal medicine3
Science: Biology (General)1
Science: Chemistry: General. Including alchemy1
Science: Chemistry1
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy1
Medicine1
Science1
Science: Science (General)1
The category Medicine: Medicine (General) 11 is the most frequently represented among the references in this article. It primarily includes studies from New England Journal of Medicine The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year